← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV14행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Technetium Tc-99m Sodium Pertechnetate (Technetium Tc-99m Sodium Pertechnetate)
Endocyte·Metastatic Endometrial Carcinoma
7 trials
Overview
Program
Technetium Tc-99m Sodium Pertechnetate
Overview
Company
Endocyte
Overview
Modality
CGT
Overview
Target
Metastatic Endometrial Carcinoma
Overview
Indication
Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
The impact of different computational assumptions in 131 I dosimetry for hyperthyroidism therapy.. The goal of the current study was to investigate the impact of different computational models on 131 I dosimetry prior to hyperthyroidism therapy. It was also aimed to highlight an accurate and cost-effective method for routine dosimetry of graves and toxic adenoma patients. A cohort of 45 patients w…
Clinical
Safety signal
The impact of different computational assumptions in 131 I dosimetry for hyperthyroidism therapy.. The goal of the current study was to investigate the impact of different computational models on 131 I dosimetry prior to hyperthyroidism therapy. It was also aimed to highlight an accurate and cost-effective method for routine dosimetry of graves and toxic adenoma patients. A cohort of 45 patients w…
Clinical
Program phase
PHASE_1